Quantcast

Latest dyslipidemia Stories

2014-11-18 16:26:22

Additional Data Analysis Showed Every Two Week and Monthly Dosing Regimens of Evolocumab Were Clinically Equivalent THOUSAND OAKS, Calif., Nov.

2014-11-10 08:34:30

THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S.

2014-10-21 08:32:43

DALLAS, October 21, 2014 /PRNewswire/ -- RnRMarketResearch.com adds EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023 market research of 94 pages to the Therapeutics

2014-10-01 20:24:10

Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia

2014-08-28 08:28:27

Represents First BLA Submission for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Aug.

2014-07-21 12:24:55

Agents That Reduce the Incidence of Cardiovascular Adverse Events Remain a Key Unmet Need for Both Physicians and Payers, According to Findings from Decision Resources Group BURLINGTON, Mass.,

2014-03-30 08:20:05

Data From Two Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented in Late-Breaking Clinical Trials Session at ACC.14 - Data Add to the Three Pivotal Studies Presented Yesterday THOUSAND

2014-03-29 16:20:11

Data From Three Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented as Featured Clinical Research at ACC.14 THOUSAND OAKS, Calif., March 29, 2014 /PRNewswire/ --

2014-03-20 12:29:12

LONDON, March 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:


Word of the Day
whirret
  • To give a box on the ear to.
The word 'whirret' may be onomatopoeic.